Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2][50]. Core Viewpoints - The FDA's recent decision to gradually eliminate animal testing requirements for monoclonal antibodies and other drugs is expected to benefit AI-driven drug development, potentially accelerating new drug approvals and reducing R&D costs [5][6][14][16]. - The pharmaceutical and biotechnology sector experienced a decline of 5.61% this week, underperforming the CSI 300 index by 2.73 percentage points, ranking 22nd among 31 sub-industries [19][24]. Summary by Sections Weekly Insights - The FDA's announcement on April 11, 2025, aims to replace animal testing with more effective and human-relevant methods, which could enhance drug safety and lower costs [14][15]. - The shift is anticipated to accelerate drug development timelines and improve success rates, particularly benefiting companies involved in AI drug development such as Jingtai Holdings and Chengdu Xian Dao [6][17]. Subsector Performance - The blood products sector saw the highest increase this week, rising by 4.06%, while the medical outsourcing sector faced the largest decline at 16.04% [7][23]. - The medical device sector decreased by 2.62%, and the traditional Chinese medicine sector fell by 3.35% [7][23]. Recommended and Benefiting Stocks - Recommended stocks include Weidian Physiotherapy, Maipu Medical, and Yingke Medical [8][31]. - Benefiting stocks from the FDA policy change include Jingtai Holdings, Chengdu Xian Dao, and Hongbo Pharmaceutical [6][17]. Detailed Subsector Analysis - **Medical Devices**: The sector is expected to benefit from the "old-for-new" policy and increased procurement activities in Q2 2025, with a current P/E ratio of 32.15, indicating potential for valuation growth [27][29]. - **Medical Consumables**: This sector is under pressure due to US-China tariff impacts, but certain segments are expected to perform well due to high growth potential and improved conditions [30]. - **IVD Sector**: The IVD sector is projected to recover as AI technologies enhance diagnostic capabilities, despite current pressures from procurement policies [33]. - **Blood Products**: The sector is expected to benefit from rising domestic production and increased focus on local sourcing due to tariff impacts [35]. - **Retail Pharmacy**: The offline pharmacy sector is seeing a recovery in customer traffic and profitability, with major players expected to leverage AI for operational efficiency [37][38].

Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2] Core Viewpoints - The FDA's recent decision to gradually eliminate animal testing requirements for monoclonal antibodies and other drugs is expected to benefit AI-driven drug development, potentially accelerating new drug approvals and reducing R&D costs [5][6][14][16] - The pharmaceutical and biotechnology sector experienced a decline of 5.61% this week, underperforming the CSI 300 index by 2.73 percentage points [19][24] - The blood products sector showed the highest increase this week, rising by 4.06%, while the medical outsourcing sector faced the largest decline, dropping by 16.04% [7][19][23] Summary by Sections Weekly Insights - The FDA's announcement on April 11, 2025, aims to replace animal testing with more effective human-relevant methods in drug development, which could enhance drug safety and lower costs [14][15] - The pharmaceutical sector's performance this week was marked by significant declines across various sub-sectors, with blood products being the only one to gain [19][23] Sub-sector Performance - Blood products increased by 4.06%, while medical outsourcing fell by 16.04%, indicating a significant divergence in performance among sub-sectors [7][19][23] - The medical device sector's P/E ratio is currently at 32.15, suggesting potential for valuation increases [27] - The IVD sector is also seen as having room for valuation growth, with a current P/E of 21.89 [33] Recommended and Benefiting Stocks - Recommended stocks include Microelectrophysiology, Maipu Medical, and Yingke Medical, among others [8][31][38] - Benefiting stocks from the FDA's policy change include Jingtai Holdings, Chengdu Xian Dao, and Hongbo Pharmaceutical [6][17] Market Trends - The report highlights a structural investment opportunity in the pharmaceutical sector, driven by policy support and AI-enabled R&D [26] - The report notes that the medical device sector is expected to benefit from upcoming procurement policies and a low base effect in Q2 2025 [27][29]

Group 1 - The core index of the China Securities Internet Medical Theme Index (CS Internet Medical, 930720) opened lower but rose, closing at 2514.46 points with a trading volume of 6.017 billion yuan [1] - Over the past month, the CS Internet Medical Theme Index has decreased by 12.73%, increased by 15.90% over the past three months, and has risen by 5.70% year-to-date [1] - The index reflects the overall performance of representative companies providing hardware, software, or services for medical informationization and intelligence [1] Group 2 - The top ten weighted companies in the CS Internet Medical Theme Index are: Yifeng Pharmacy (6.65%), Daclin (6.44%), Laobaixing (6.21%), Wandong Medical (5.53%), Haier Biomedical (5.48%), Jiuzhoutong (5.44%), Yixintang (5.37%), Aier Eye Hospital (5.33%), Yuyue Medical (5.28%), and Lepu Medical (5.17%) [1] - The market share of the CS Internet Medical Theme Index holdings is 51.03% from the Shenzhen Stock Exchange and 48.97% from the Shanghai Stock Exchange [1] - The industry composition of the index holdings shows that 70.41% is in pharmaceuticals and healthcare, 25.78% in information technology, and 3.81% in communication services [1] Group 3 - The index samples are adjusted quarterly, with adjustments implemented on the next trading day after the second Friday of March, June, September, and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made under special circumstances [2] Group 4 - Public funds tracking the CS Internet Medical Index include: Huatai-PineBridge China Securities Internet Medical A and Huatai-PineBridge China Securities Internet Medical C [3]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [2][29]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 5.20% from March 28 to April 10, 2025, which is approximately 0.18 percentage points lower than the index [14][29]. - Most sub-sectors within the industry recorded negative returns during the same period, with blood products and offline pharmacy sectors showing gains of 7.36% and 1.41%, respectively, while medical R&D outsourcing and in vitro diagnostics faced declines of 21.38% and 10.62% [15][29]. - Approximately 17% of stocks in the industry recorded positive returns, while around 83% experienced negative returns during the reporting period [16][19]. - The overall price-to-earnings (PE) ratio for the SW pharmaceutical and biotechnology industry is approximately 38.81 times, which is 3.38 times relative to the CSI 300, indicating a decline in industry valuation and positioning at a relatively low level compared to recent years [20][29]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, with a decline of 5.20% from March 28 to April 10, 2025 [14]. - Most sub-sectors recorded negative returns, with blood products and offline pharmacies leading in gains [15]. - About 17% of stocks in the industry had positive returns, while 83% had negative returns [16]. 2. Industry News - The national Chinese medicine procurement alliance began centralized procurement and information maintenance for selected drugs starting April 9, 2025, involving 20 product groups and 95 products, with 174 drugs selected [26]. 3. Important Announcements from Listed Companies - Zai Lab received approval for clinical trials of its drug ZG005 for use in combination with chemotherapy for digestive tumors [27]. - Opcon Vision received a medical device registration certificate for its orthokeratology contact lenses [28]. 4. Industry Weekly Perspective - The report suggests focusing on investment opportunities in medical devices and innovative drugs, particularly those with import substitution potential [29]. - Recommended stocks include Mindray Medical, Yuyuan Pharmaceutical, and others across various segments such as medical aesthetics and innovative drugs [30].

关于贯彻落实"提质增效重回报" 专项行动暨控股股东提议实施 益丰大药房连锁股份有限公司 2024年度现金分红的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 证券代码：603939 证券简称：益丰药房 公告编号：2025-027 债券代码：113682 债券简称：益丰转债 董事会 2025年4月8日 特此公告。 益丰大药房连锁股份有限公司 益丰大药房连锁股份有限公司（以下简称"本公司"或"公司"）于2025年4月8日收到公司控股股东宁波梅 山保税港区厚信创业投资合伙企业（有限合伙）（以下简称"厚信创投"）出具的《关于2024年度现金分 红提议的函》，现将相关情况公告如下。 基于对本公司未来发展前景的信心，为推动公司积极响应新"国九条"并落实"提质增效重回报"专项行 动，切实维护广大投资者利益，促进公司内在价值合理回归，公司控股股东厚信创投提议：以实施2024 年度权益分派的股权登记日登记的总股本为基数，向全体股东派发现金红利，2024年度派发现金红利的 总额（含2024年半年度已实施的现金分红）不低于经审计的公司2 ...

Investment Rating - The report maintains a "Recommended" rating for the industry, indicating a positive outlook for the sector's fundamentals and expectations for the industry index to outperform the benchmark index [4]. Core Insights - The pharmaceutical industry is primarily driven by domestic demand, with most sub-sectors minimally affected by tariff impacts, such as medical services, innovative domestic drugs, traditional Chinese medicine, and pharmacy/retail [1][3]. - There is significant potential for import substitution in high-import sectors like blood products, certain medical devices, and key components, which are expected to benefit marginally from the current tariff situation [1]. - The report highlights specific sectors to watch, including blood products, domestic consumption-related sectors, and medical devices, which are poised for growth due to favorable policies and market conditions [2]. Summary by Relevant Sections Blood Products - The overseas share of human albumin exceeds 60%, and with tariffs on imported albumin, domestic prices are expected to recover. The "14th Five-Year Plan" for new plasma stations is also promising. Companies to focus on include Palin Biotech, Tiantan Biological, and Boya Biological [2]. Domestic Consumption - External impacts are minimal, and consumption policies are catalyzing recovery in certain areas. Key companies include medical services (e.g., Aier Eye Hospital, Tongce Medical), beauty services (Aimeike), pharmacies (Yifeng Pharmacy, Dazhong Pharmacy), and traditional Chinese medicine (Dong-E E-Jiao, China Resources Sanjiu) [2]. Medical Devices - For core components, the domestic market for medical CT tubes is largely dominated by imports, with potential benefits from anti-dumping investigations. Companies to watch include Yirui Technology and United Imaging Healthcare [2]. - In consumables, the domestic market for electrophysiology is under 10% localization, with U.S. companies leading. Companies like Huitai Medical and Microelectrophysiology are expected to benefit from increased localization [2]. - In vitro diagnostics (IVD) are also highlighted, with certain leading foreign companies facing tariffs that may accelerate import substitution. Recommended companies include New Industries, Mindray Medical, Antu Biology, and Yanhui Long [2]. Pharmaceuticals - The report indicates that the pharmaceutical sector is largely unaffected by tariffs, with a focus on domestic innovation. Companies to monitor include Heng Rui Medicine, Innovent Biologics, and Fuhong Hanlin [3].

Group 1 - The Shanghai Health Industry Index closed at 1065.07 points, with a 2.99% increase over the past month, a 0.09% decrease over the past three months, and a 0.09% decline year-to-date [1] - The index comprises the 50 largest listed companies in the healthcare, food safety, and environmental protection sectors on the Shanghai Stock Exchange, using equal weighting to reflect the overall performance of these companies [1] - The top ten weighted companies in the index include Fulongma (3.18%), Borui Pharmaceutical (2.57%), Daotong Technology (2.44%), WuXi AppTec (2.37%), Yifeng Pharmacy (2.21%), Hanlan Environment (2.21%), Bright Meat (2.20%), Longjing Environmental Protection (2.16%), Huitai Medical (2.16%), and Juxing Agriculture and Animal Husbandry (2.15%) [1] Group 2 - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December, with a sample adjustment ratio generally not exceeding 20% [2] - Weight factors are adjusted along with the sample changes, and remain fixed until the next scheduled adjustment unless a special situation arises [2] - Companies that are delisted or undergo mergers, acquisitions, or splits are handled according to the calculation and maintenance guidelines [2]

平均一天要倒闭 274 家 2024 年 11 月的一个午后，王宁脚步匆匆，正赶往医院。路过街角一家药店时，他眼角余光瞥见玻璃 门上贴着一张 A4 纸，纸张褶皱，上面字迹歪扭，写着 "店长调货去了，马上就回" 。 王宁下意识地透过玻璃朝店内张望，这一望，心里满是诧异。货架上空空荡荡，厚厚的灰尘在阳光的 直射下无所遁形，怎么看都不像是马上要营业的样子，倒像关门许久了。他向路过的居民打听："这 家店开了不到一年吧？" 对方笑着回他："半年都撑不到。" 药店倒闭并非个例。社交平台上，有不少相关的帖子，有人称："药店突然倒闭，你们现在都在干什 么？" 一位药店工作人员回复："我们晚上正上班呢，老板突然进来，说不干了，大家立刻打包，一 会儿就把东西搬空了。" 发帖人也分享自身经历："今天还在上班，明天店就撤了。" 曾几何时，街角的药店仿佛一夜之间成了城市的主角，像雨后春笋般疯狂生长。处方药柜里的高毛利 商品，撑起了一个个财富神话。百米长的街道上，四五家药店比邻而居，仿佛在比拼谁更能吸引顾客 的目光。那时的场景，荒诞却真实，资本在这片小小的战场上狂欢，药店成了这场盛宴的主角。 然而，时过境迁，如今推开那些贴着"旺铺转租" ...

Investment Rating - The report maintains an "Overweight" rating for the industry [5] Core Views - The recent issuance of the "Special Action Plan to Boost Consumption" by the Central and State Offices is expected to significantly stimulate consumption, leading to a recovery in the consumer healthcare sector [3][5] - The report highlights that the medical service industry's performance is anticipated to improve due to better expectations and technological upgrades, despite facing challenges in 2024 [5] - The report identifies specific companies that are expected to benefit from these trends, including Aier Eye Hospital, Puren Eye Hospital, Tongce Medical, and others, all rated as "Overweight" [5] Summary by Sections Industry Overview - The report emphasizes the potential for a recovery in consumer healthcare driven by government policies aimed at boosting consumption [3][5] Investment Highlights - The report notes that the medical service sector is experiencing a slowdown in revenue growth due to external pressures, but demand remains strong, suggesting a rebound as economic conditions improve [5] - New surgical techniques and the implementation of supportive policies are expected to stabilize and enhance the average transaction value in consumer healthcare [5] - The home medical device market is projected to benefit from policies encouraging aging-friendly transformations and increased investment in healthcare and elderly care [5] Company-Specific Insights - The report lists several companies with "Overweight" ratings, including Aier Eye Hospital (market cap: 134 billion, projected net profit for 2024: 35.96 billion), Puren Eye Hospital, and others, indicating strong growth potential [6] - Companies like Kefu Medical and Meihua Medical are also highlighted as beneficiaries of the favorable policy environment, although they are not yet rated [5][6]

Core Viewpoint - The retail pharmacy industry, once thriving and profitable, is experiencing a significant decline, with an estimated 39,000 stores expected to close in 2024, marking a closure rate of 5.7%, up from 3.8% in 2023 [5][12]. Industry Overview - The rapid growth of retail pharmacies in urban areas has transformed them into a prominent feature of city life, with high-margin prescription drugs contributing to wealth creation [1]. - The once lucrative business model, characterized by a 40% profit margin and stable income from insurance reimbursements, is now under threat [7][9]. Current Challenges - Increased market competition, particularly from online pharmacies offering lower prices and faster delivery, has severely impacted traditional brick-and-mortar stores [9][10]. - The saturation of the market, with numerous pharmacies opening in close proximity, has further compressed profit margins, leading to an average sales decline of 10.6% in the first half of 2024 [12]. Financial Performance - Many listed pharmacy chains are forecasting significant profit declines, with some expecting net profits to drop by as much as 72.7% [12]. - The tightening of healthcare insurance policies has exacerbated the situation, as many pharmacies rely heavily on insurance reimbursements, which have become increasingly scrutinized [13]. Conclusion - The once prosperous era for retail pharmacies is rapidly coming to an end, with closures accelerating and the industry facing unprecedented challenges [14].